These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34655050)

  • 21. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
    Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
    J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients.
    Wojenski DJ; Bartoo GT; Merten JA; Dierkhising RA; Barajas MR; El-Azhary RA; Wilson JW; Plevak MF; Hogan WJ; Litzow MR; Patnaik MM; Wolf RC; Hashmi SK
    Transpl Infect Dis; 2015 Apr; 17(2):250-8. PubMed ID: 25661996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.
    Han K; Bies R; Johnson H; Capitano B; Venkataramanan R
    Clin Pharmacokinet; 2011 Mar; 50(3):201-14. PubMed ID: 21294597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study.
    Zhang Y; Zhang X; Zou Y; Sun Y; Li X
    Xenobiotica; 2021 Dec; 51(12):1408-1415. PubMed ID: 34983304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
    McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance.
    Ling J; Yang XP; Dong LL; Jiang Y; Zou SL; Hu N; Chen R
    J Clin Pharm Ther; 2022 Apr; 47(4):483-492. PubMed ID: 34779003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
    Cho JC; Le AD; Locke SC
    Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan.
    Hiraishi I; Ueno R; Watanabe A; Maekawa S
    Clin Drug Investig; 2021 Dec; 41(12):1075-1086. PubMed ID: 34784011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
    Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation.
    Mimura A; Yamaori S; Ikemura N; Katsuyama Y; Matsuzawa N; Ohmori S
    J Clin Pharm Ther; 2019 Aug; 44(4):565-571. PubMed ID: 30950099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of cyclosporine A in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation.
    Cai R; Zhang L; Wu T; Huang Y; Lu J; Huang T; Wu Y; Wu D; Qi J; Niu L; Xiao Y; Chen X; Liu Y; Luo Y; Liu T
    Eur J Clin Pharmacol; 2024 May; 80(5):685-696. PubMed ID: 38329479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
    Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
    Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
    Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole.
    Barajas MR; McCullough KB; Merten JA; Dierkhising RA; Bartoo GT; Hashmi SK; Hogan WJ; Litzow MR; Patnaik MM; Wilson JW; Wolf RC; Wermers RA
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):579-83. PubMed ID: 26524731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
    Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
    J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
    Chemaly RF; Ullmann AJ; Stoelben S; Richard MP; Bornhäuser M; Groth C; Einsele H; Silverman M; Mullane KM; Brown J; Nowak H; Kölling K; Stobernack HP; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Champlin RE; Ehninger G;
    N Engl J Med; 2014 May; 370(19):1781-9. PubMed ID: 24806159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.